Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Biodesix ( (BDSX) ).
On September 26, 2025, Biodesix, Inc. announced that it has regained compliance with the Nasdaq’s minimum bid price requirement, ensuring its continued listing on The Nasdaq Global Market. This follows a previous notification in March 2025, when the company’s stock had fallen below the $1.00 per share minimum, but has now maintained a closing bid price of at least $1.00 for ten consecutive business days, resolving the issue.
The most recent analyst rating on (BDSX) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Biodesix stock, see the BDSX Stock Forecast page.
Spark’s Take on BDSX Stock
According to Spark, TipRanks’ AI Analyst, BDSX is a Neutral.
Biodesix’s overall stock score is primarily impacted by its financial instability, with high leverage and negative profitability. While there is revenue growth and improved gross margins, the lack of profitability and negative valuation metrics weigh heavily on the score. The earnings call provides some optimism with strategic growth plans, but increased expenses and net loss remain concerns.
To see Spark’s full report on BDSX stock, click here.
More about Biodesix
Biodesix, Inc. is a company operating in the biotechnology industry, focusing on the development and commercialization of diagnostic tests that support treatment decisions and improve patient outcomes.
Average Trading Volume: 150,495
Technical Sentiment Signal: Sell
Current Market Cap: $61.92M
Find detailed analytics on BDSX stock on TipRanks’ Stock Analysis page.